Sanofi and its U.S. partner Regeneron said on Thursday the U.S. Food and Drug Administration had designated their dupilumab drug as "breakthrough therapy" in the treatment of atopic dermatitis, a chronic form of eczema, granting the product a fast-track development and review process. Dupilumab is also being studied in the treatment of asthma and chronic sinusitis with nasal polyps and is seen by both companies and financial analysts as a potential blockbuster.
Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. Shares of SNY fell by 0.56% or $-0.27/share to $48.09. In the past year, the shares have traded as low as $44.50 and as high as $57.42. On average, 2058630 shares of SNY exchange hands on a given day and today's volume is recorded at 1636666.
Source
